94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002473-61-BE16/12/201302/09/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 18.0Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2France;United States;Canada;Spain;Belgium;Denmark;Norway;Netherlands;Germany;Italy;United Kingdom;Sweden
2EUCTR2012-002473-61-NL12/12/201304/10/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 18.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2France;United States;Canada;Belgium;Spain;Denmark;Germany;Netherlands;Italy;United Kingdom;Sweden
3EUCTR2012-002473-61-SE26/06/201320/03/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 18.0Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2United States;Canada;Belgium;Spain;Denmark;Netherlands;Italy;United Kingdom;Sweden
4EUCTR2012-002473-61-ES21/06/201309/04/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 14.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2United States;Canada;Belgium;Spain;Denmark;Netherlands;Italy;United Kingdom;Sweden
5EUCTR2012-002473-61-IT18/06/201304/04/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 14.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Simtuzumab
Product Code: GS-6624
INN or Proposed INN: Simtuzimab
Product Name: Simtuzimab
Product Code: GS-6624
INN or Proposed INN: Simtuzimab
Gilead Sciences IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2United States;Canada;Denmark;United Kingdom;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-002473-61-GB17/05/201313/03/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 17.0 Level: LLT Classification code 10036732 Term: Primary sclerosing cholangitis System Organ Class: 100000004871 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Gilead Sciences IncNULLNot Recruiting Female: yes
Male: yes
225 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noFrance;United States;Canada;Belgium;Spain;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
7EUCTR2012-002473-61-DK14/05/201308/04/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 17.0Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2United States;Canada;Belgium;Spain;Denmark;Netherlands;Italy;United Kingdom;Sweden
8EUCTR2012-002473-61-DE08/05/201308/03/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 17.0Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Code: GS-6624
INN or Proposed INN: GS-6624
INN or Proposed INN: GS-6624
Gilead Sciences IncNULLNot RecruitingFemale: yes
Male: yes
225Phase 2France;United States;Canada;Belgium;Spain;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
9NCT01672853March 4, 201322/8/2012Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC)Biological: Simtuzumab;Biological: PlaceboGilead SciencesNULLCompleted18 Years70 YearsAll235Phase 2United States;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom